The Research Case for Recognising the Co-occurring Presentation of Autism and ADHD as a Distinct Clinical Entity

If you have been diagnosed with both autism and ADHD, or if you are in the process of being assessed for one while suspecting the other, you already know that something does not add up. You have been handed two separate explanatory frameworks and told to stack them. But the experience does not feel like two things stacked. It feels like one very specific, very particular thing that neither framework fully captures. The research is starting to agree with you.

This post makes the case that the co-occurring presentation of autism and ADHD is not additive — it is not autism plus ADHD, any more than water is hydrogen plus oxygen sitting in a bowl together. The neurological, genetic, and clinical evidence supports recognising the combined presentation as its own distinct entity, with its own diagnostic criteria, its own research agenda, and its own clinical pathway. The community term AuDHD captures something real. The clinical infrastructure does not yet exist to serve the people it names.

The short answer: Approximately 40% of autistic people also meet criteria for ADHD. The two conditions share genetic architecture, produce a neurologically distinct brain profile when combined, and generate a clinical presentation that is demonstrably different from either condition alone. Yet no formal diagnostic category exists for this combined presentation. This post reviews the peer-reviewed evidence and argues that needs to change.

What does the research actually say about how common AuDHD is?

The short answer is: very common, and probably more common than the numbers currently suggest.

The first comprehensive meta-analysis specifically designed to estimate both current and lifetime prevalence of ADHD in autistic populations was published in 2021. Rong et al. drew on 63 studies published between 2000 and 2020, covering databases including PubMed, Web of Science, PsycINFO, CINAHL, and Embase. The pooled current prevalence of ADHD in autistic individuals was 38.5% (95% CI: 34.0–43.2%), and the lifetime prevalence was 40.2% (95% CI: 34.9–45.7%) (Rong et al., 2021). That means roughly four in ten autistic people also have ADHD.

Rong, Y., Yang, C.-J., Jin, Y., & Wang, Y. (2021). Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis. Research in Autism Spectrum Disorders, 83, 101759. https://doi.org/10.1016/j.rasd.2021.101759

A 2024 school-population study in Spain, the EPINED study, added important nuance. Canals et al. used a rigorous two-phase design, screening 3,727 parents and teachers and then individually assessing 781 children using DSM-5 criteria. They found ADHD co-occurring in 32.8% of autistic children. But the finding that should stop anyone in their tracks is this: only 15.8% of children who met criteria for both conditions had previously been diagnosed with both (Canals et al., 2024). That means 84.2% were being seen and treated through a single diagnostic lens when their clinical reality required two.

Canals, J., Morales-Hidalgo, P., Voltas, N., & Hernandez-Martinez, C. (2024). Prevalence of comorbidity of autism and ADHD and associated characteristics in school population: EPINED study. Autism Research, 17(6), 1276-1286. https://doi.org/10.1002/aur.3146

These numbers are almost certainly undercounts. The studies that generated them are predominantly paediatric, male-skewed, and drawn from clinic or school populations in Western countries. Women and girls with both conditions are significantly less likely to have received an autism diagnosis in childhood. If you were not diagnosed as autistic, you were not in these studies. The real rate of ADHD co-occurrence in adult autistic women is likely to be substantially higher than 38.5%, and the evidence base to answer that question with any precision does not yet exist.

For organisations: If 32–40% of autistic employees also have ADHD, your organisation is very likely employing people with the combined presentation without knowing it. Workplace adjustments designed for autism alone, or ADHD alone, will not address the oscillatory regulatory profile of the combined presentation. Stacking two separate sets of guidance is not the same as understanding how those two sets interact.

Why is the AuDHD presentation not just autism plus ADHD?

This is the most important clinical question in this space, and the answer is becoming clearer. The combined presentation is not additive. It produces a distinct neurological profile that neither condition alone predicts.

What the neuroimaging shows

A 2023 study published in eNeuro, the open-access journal of the Society for Neuroscience, directly compared brain dynamics in four matched groups: children with autism only, ADHD only, both conditions, and typically developing controls. All groups were matched for age, sex, and IQ — a methodological strength that most studies in this area fail to achieve.

The researchers, Watanabe and Watanabe (2023), found that the ADHD-like cognitive instability in children with the combined presentation was driven by a completely different brain mechanism than the same symptom in children with ADHD alone. In pure ADHD, cognitive instability is associated with overly flexible whole-brain dynamics originating in the dorsal attention network. In the combined group, the same surface-level symptom was driven by atypical activity in the frontoparietal control network and left prefrontal cortex — a mechanism not seen in either pure condition. The authors concluded that the co-occurring condition would require its own bespoke diagnosis and treatment approach.

Watanabe, D., & Watanabe, T. (2023). Distinct frontoparietal brain dynamics underlying the co-occurrence of autism and ADHD. eNeuro, 10(7), ENEURO.0146-23.2023. https://doi.org/10.1523/ENEURO.0146-23.2023

What the clinical phenotyping shows

Carta et al. (2020) used the Child Behavior Checklist to compare emotional and behavioural profiles across children with autism only, ADHD only, and the combined presentation. They found that children with both conditions occupied an intermediate clinical profile that was not simply the worst of both. The combined group showed lower externalising problems than ADHD alone and higher externalising problems than autism alone (p < 0.000 for both comparisons), with no significant difference in internalising problems across groups. An intermediate, non-additive phenotype.

Carta, A., Fucà, E., Guerrera, S., Napoli, E., Valeri, G., & Vicari, S. (2020). Characterization of clinical manifestations in the co-occurring phenotype of attention deficit/hyperactivity disorder and autism spectrum disorder. Frontiers in Psychology, 11, 861. https://doi.org/10.3389/fpsyg.2020.00861

A 2026 review in Psychiatric Annals examined the adult co-occurring presentation specifically, finding that impulsivity and attentional inconsistency from ADHD interact with autistic rigidity, sensory sensitivities, and social-cognitive differences to amplify executive, emotional, and social-communication difficulties — not merely sum them (Wulf et al., 2026). Amplification, not addition. The distinction matters clinically.

Wulf, C., Kobryn, S., Ferretti, C., Rahman, A. M., & Hollander, E. (2026). Autism spectrum disorder and attention-deficit/hyperactivity disorder overlap and comorbidity in adults. Psychiatric Annals, 56(3), e65-e70. https://doi.org/10.3928/00485713-20260113-03

Why lived experience matches the science

The autistic nervous system is oriented towards predictability. Routine is a regulatory strategy, not a personality quirk. It is how a nervous system that processes sensory information at higher intensity and with less automatic filtering manages the load of being alive. The ADHD nervous system, meanwhile, operates on a dopaminergic deficit model that drives it neurochemically towards novelty, stimulation, and variable reward. It is poorly equipped to sustain engagement with predictable, low-stimulation environments.

In the combined presentation, these two drives do not average out. They do not find a comfortable middle ground. They produce oscillation: a state of being simultaneously pulled towards predictability and pulled away from it, often within the same task, the same hour, the same decision. This is not a metaphor. It is what the Watanabe and Watanabe (2023) frontoparietal data is describing at a neurological level.

For the late-diagnosed adult who spent decades being told they were contradictory, inconsistent, or self-sabotaging — this is what that felt like from the inside. The science is catching up to the experience.

For organisations: The oscillatory regulatory profile has direct workplace implications. An employee with the combined presentation may need structure and predictability to regulate (autistic drive) while simultaneously finding rigid, repetitive, low-stimulation tasks intolerable (ADHD drive). These are not contradictory requests. They are the predictable outputs of a nervous system with two competing regulatory needs. Designing for both simultaneously is possible, but it requires understanding what you are actually dealing with.

Is AuDHD genetic? What does the heritability research tell us?

The co-occurrence of autism and ADHD is not random. It has a shared genetic substrate, and that substrate is well-documented.

Rommelse et al. (2010), in a comprehensive review of all available genetic evidence at that time — family studies, twin studies, candidate gene studies, linkage studies, and genome-wide association studies — concluded that family and twin studies consistently support the hypothesis that ADHD and autism share partly overlapping familial and genetic factors. Both conditions individually show heritability estimates of approximately 70–80%, with a substantial portion of that heritability shared between the two (Rommelse et al., 2010).

Rommelse, N. N. J., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010). Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. European Child and Adolescent Psychiatry, 19(3), 281-295. https://doi.org/10.1007/s00787-010-0092-x

At the molecular level, Ma et al. (2021) investigated whether variants in the SHANK gene family — already implicated in autism through synapse development research — also showed overlap with ADHD and with the combined presentation. Using a Hong Kong clinical sample of 298 boys with ADHD, 134 with autism, 109 with both, and 232 typically developing controls, they identified specific single nucleotide polymorphisms in the SHANK2 gene that showed significant association across all three clinical groups. The ADHD+ASD group showed the strongest signals at some variants, consistent with a pleiotropic genetic model — one gene, multiple conditions (Ma et al., 2021).

Ma, S.-L., Chen, L. H., Lee, C.-C., Lai, K. Y. C., Hung, S.-F., Tang, C.-P., Ho, T.-P., Shea, C., Mo, F., Mak, T. S. H., Sham, P.-C., & Leung, P. W. L. (2021). Genetic overlap between attention deficit/hyperactivity disorder and autism spectrum disorder in SHANK2 gene. Frontiers in Neuroscience, 15, 649588. https://doi.org/10.3389/fnins.2021.649588

What this means practically: if you are an autistic adult who was also diagnosed with ADHD, or vice versa, and you look around your family and see patterns — the parent who was never diagnosed but you now recognise, the sibling cluster, the family history that clinicians often dismiss as anecdote — the heritability evidence is not surprised by any of that. The co-occurrence in families is not coincidence. It reflects shared genetic architecture that existed long before anyone had the language to name it.

The historical prohibition on dual diagnosis under DSM-IV (1994–2013) did not mean the co-occurrence was not happening. It meant clinicians and researchers were not looking for it, and the genetic signals were being generated by populations whose diagnostic situation the DSM had formally prevented from existing. Swedish monozygotic twin data published before DSM-5 showed that the co-twins of autistic individuals had an odds ratio of 17.77 for ADHD compared to dizygotic co-twins — evidence the diagnostic system was simply choosing not to act on.

For organisations: The heritability data has a practical implication for organisations: the combined presentation clusters in families. If one employee discloses a late diagnosis of autism or ADHD, there is a statistically elevated probability that other family members are also neurodivergent. This is relevant context for designing supportive leave policies, Employee Assistance Programme offerings, and the language used in disclosures conversations.

Why do so many AuDHD people get misdiagnosed with BPD or bipolar disorder?

Without a formal clinical category for the combined presentation, clinicians attempt to make sense of a complex neurological profile using frameworks that were not designed for it. The predictable result is misdiagnosis — and the patterns are documented.

Borderline Personality Disorder is the misdiagnosis most consistently associated with late-diagnosed autistic women and AuDHD women. A 2024 conference paper by Sholinghur, presented at the European Psychiatry Association congress, examined the diagnostic overlap between autism and BPD in young females, finding that autistic girls and women may be at elevated risk for misdiagnosis with BPD because of the ways their autistic presentations are miscategorised against personality disorder criteria (Sholinghur, 2024).

Sholinghur, H. (2024). Misdiagnosis in young females: Autism versus Borderline Personality Disorders. European Psychiatry, 67(S1), S282. https://doi.org/10.1192/j.eurpsy.2024.282

This is not a rare or fringe finding. The emotional dysregulation that drives BPD misdiagnosis in this population is real and neurologically grounded. Research on emotional dysregulation in ADHD consistently identifies it in 70–80% of people with the condition. In the combined presentation, this sits alongside the autistic nervous system’s elevated sensory and emotional intensity. The meltdowns, the shutdowns, the apparent instability — these are measurable neurological phenomena. They are not character pathology.

The mechanism of misdiagnosis is not difficult to understand once you know what you are looking at. BPD and AuDHD share enough surface features — emotional lability, relationship difficulties, impulsivity, identity disturbance — that a clinician who is not looking for autism, who has not been trained to recognise autism in women, or who is working within a diagnostic framework that treats BPD as a default for emotionally dysregulated women, will find what they are looking for.

Other documented misdiagnoses in this population include bipolar disorder, complex PTSD, and Oppositional Defiant Disorder. Each incorrect diagnosis represents time lost, treatment harm accrued, and an individual spending years trying to understand themselves through a framework that does not fit.

The Wulf et al. (2026) review in Psychiatric Annals identifies symptom masking as a core diagnostic barrier in adults — masking being the cognitive and behavioural work of suppressing or compensating for autistic and ADHD traits to appear neurotypical. Decades of masking do not just make diagnosis harder. They produce cumulative burnout, anxiety, and a clinical presentation that can look like multiple other conditions depending on what the clinician already expects to see.

For organisations: Misdiagnosis is not only a healthcare system problem. It is a workplace problem. An employee who has spent years being treated for BPD or bipolar disorder when their underlying profile is AuDHD has probably been failed by every system they have encountered, including previous employers. When they arrive in your organisation — possibly late-diagnosed, possibly mid-burnout, possibly carrying significant iatrogenic harm from incorrect treatment — they need a workplace that responds to what their nervous system actually needs, not what a previous incorrect diagnosis suggested.

Why does stimulant medication not work the same way in AuDHD?

Stimulant medication is the first-line pharmacological treatment for ADHD. In populations without autism, response rates are well established: approximately 85% of school-age children with ADHD alone will respond positively to some form of stimulant. The picture in the combined population is substantially different, and the clinical guidance does not adequately reflect this.

Stimulants do not appear to work the same way in people with co-occurring autism and ADHD. While they may produce some improvement in attentional symptoms, they commonly increase sensory hypersensitivity, worsen cognitive rigidity, elevate anxiety, and intensify repetitive behaviours in autistic individuals (Joshi et al., 2020). This is not a minor side-effect profile issue. It is a fundamental treatment-response paradox that flows directly from the interaction of two neurological systems.

The autistic nervous system’s sensory processing profile interacts with the dopaminergic mechanism of stimulants in ways that are not yet fully understood. When a stimulant medication increases focus, that focus can go one of two ways. It can improve on-task attention. Or it can intensify the autistic drive towards a single point of interest, increase sensory hypervigilance, and make task-switching even harder. The individual gets more focused — but focused on the wrong thing, or locked into a pattern they cannot exit.

The Wulf et al. (2026) adult review recommends integrated treatment approaches: cautious stimulant use where indicated, targeted non-stimulants, CBT adapted to autistic cognition, executive function coaching, and environmental modifications across work and home. That is a meaningfully different treatment approach from what either condition alone would generate — and it requires clinicians to be working within a framework that acknowledges the combined presentation as its own entity.

There are currently no clinical trials designed specifically for the co-occurring presentation as a primary study population. This is a direct consequence of the absence of a formal diagnostic category. You cannot run a clinical trial on a population that the diagnostic system has not formally named.

For organisations: For HR and managers: medication status is private. But understanding that someone with the combined presentation may be navigating a complex and still-evolving pharmacological situation — one where standard ADHD medications may have paradoxical effects — is relevant context for conversations about performance, attendance, and reasonable adjustment. The solution is rarely ‘take your medication correctly.’ The solution is usually ‘build an environment that reduces the sensory and regulatory load.’

Why should we petition the DSM to formally recognise the combined presentation?

The DSM is not a static document. It changes when the evidence demands it and when advocates and clinicians make a sustained, coordinated case for change. The history of neurodevelopmental diagnosis is a history of correction.

Under DSM-IV (1994), a diagnosis of ADHD in the presence of autism was explicitly prohibited. The clinical harm caused by that prohibition was documented for two decades — in misdiagnosis rates, in missed treatments, in research populations that excluded the very people most likely to carry the strongest signals of shared genetic architecture. In 2013, DSM-5 reversed the prohibition. The prohibition had lasted 33 years.

We are now in an analogous position. The evidence that the combined presentation constitutes a distinct neurological profile is present and growing. The evidence that 1 + 1 does not equal 2 is peer-reviewed and replicable. The evidence of clinical harm from inadequate diagnostic recognition is documented. What is missing is the formal petition and the coordinated advocacy to act on what the research has been saying.

What would a formal category need to demonstrate?

A formal diagnostic category for the combined presentation would need to show: a consistent, recognisable cluster of signs and symptoms; evidence of shared underlying mechanism; demonstrated clinical utility in improving diagnostic accuracy and treatment outcomes; and meaningful differentiation from existing categories. The current evidence base addresses all four of these, at least partially.

The neuroimaging evidence from Watanabe and Watanabe (2023) establishes distinct brain dynamics. The genetic evidence from Rommelse et al. (2010) and Ma et al. (2021) establishes shared heritability and molecular candidates. The clinical phenotyping from Carta et al. (2020) establishes a non-additive intermediate phenotype. The misdiagnosis data establishes clinical harm from non-recognition. The treatment response data from Wulf et al. (2026) establishes the need for specific clinical guidance.

A petition at this stage would be an argument for the field to build what is still missing — adult-specific diagnostic tools, sex and gender disaggregated prevalence data, clinical trials designed for the combined population — not a claim that the work is complete. Names are not conclusions. They are starting points. You name the thing, and then you build the research infrastructure around the name.

What should the name be?

AuDHD is the community’s word and should remain so. It belongs to lived experience discourse and the people who built it. A clinical term needs to do different work: it needs to communicate the underlying mechanism to clinicians who encounter it, travel across health systems without confusion, and carry the weight of diagnostic criteria and treatment protocols.

One proposal is Oscillatory Dysregulation Syndrome (ODS). ‘Oscillatory’ names the defining clinical feature: the involuntary oscillation between the autistic drive towards predictability and the ADHD drive towards novelty, which produces a regulatory pattern that neither condition independently generates. ‘Dysregulation’ is already established in clinical neurodevelopmental language and positions the presentation accurately as a nervous system structural issue rather than a behavioural problem. ‘Syndrome’ is the appropriate taxonomic category: a recognisable cluster of signs and symptoms with shared underlying mechanism, even where full aetiology is not yet established. Tourette Syndrome, Rett Syndrome, and Prader-Willi Syndrome all carry the same clinical weight as disorder-classified conditions.

ODS is a working proposal, not a finished argument. The point is that the clinical community needs to start having this conversation formally, not just in journal supplements and conference abstracts.

For organisations: Organisations that engage with disability inclusion frameworks — the UN Convention on the Rights of Persons with Disabilities, the UK Equality Act, New Zealand’s Employment Relations Act — are increasingly being asked to accommodate presentations that sit at the intersection of multiple diagnostic categories. A formal clinical term for the combined presentation would make workplace accommodation frameworks clearer, more actionable, and less reliant on individual employees having to educate their managers about how their two separate diagnoses interact. It would also reduce the risk that accommodation plans designed for one condition inadvertently worsen outcomes for the other.

What does this mean for late-diagnosed AuDHD adults?

If you were diagnosed late — in your thirties, forties, or fifties — you were probably in that 84.2% for most of your life. Assessed through one lens at a time. Told your symptoms were anxiety, or a personality disorder, or emotional immaturity, or just how you are. Given medication that helped one thing and worsened three others. Asked to explain yourself to systems that had no framework for what you were actually presenting.

The research is not yet where it needs to be. The clinical tools for adults do not exist yet. The clinical trials have not been run. The DSM category has not been created. But the neuroimaging data, the genetic data, the phenotyping data, and the misdiagnosis data are converging on the same conclusion: the combined presentation is real, it is distinct, and it has been structurally invisible for too long.

The community built AuDHD. The community deserves a clinical infrastructure built around the reality that word describes. Petitioning the DSM is not a demand for a label. It is a demand for the research, the diagnostic tools, the treatment protocols, and the funding that a named population can access. It is a demand for the 84.2% to have somewhere to land.

References

Canals, J., Morales-Hidalgo, P., Voltas, N., & Hernandez-Martinez, C. (2024). Prevalence of comorbidity of autism and ADHD and associated characteristics in school population: EPINED study. Autism Research, 17(6), 1276-1286. https://doi.org/10.1002/aur.3146

Carta, A., Fucà, E., Guerrera, S., Napoli, E., Valeri, G., & Vicari, S. (2020). Characterization of clinical manifestations in the co-occurring phenotype of attention deficit/hyperactivity disorder and autism spectrum disorder. Frontiers in Psychology, 11, 861. https://doi.org/10.3389/fpsyg.2020.00861

Joshi, G., Faraone, S. V., Wozniak, J., Petty, C., Fried, R., Galdo, M., & Biederman, J. (2020). Pharmacotherapy of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. Journal of Clinical Psychiatry, 81(5). https://doi.org/10.4088/JCP.19r13230

Ma, S.-L., Chen, L. H., Lee, C.-C., Lai, K. Y. C., Hung, S.-F., Tang, C.-P., Ho, T.-P., Shea, C., Mo, F., Mak, T. S. H., Sham, P.-C., & Leung, P. W. L. (2021). Genetic overlap between attention deficit/hyperactivity disorder and autism spectrum disorder in SHANK2 gene. Frontiers in Neuroscience, 15, 649588. https://doi.org/10.3389/fnins.2021.649588

Rommelse, N. N. J., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010). Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. European Child and Adolescent Psychiatry, 19(3), 281-295. https://doi.org/10.1007/s00787-010-0092-x

Rong, Y., Yang, C.-J., Jin, Y., & Wang, Y. (2021). Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis. Research in Autism Spectrum Disorders, 83, 101759. https://doi.org/10.1016/j.rasd.2021.101759

Sholinghur, H. (2024). Misdiagnosis in young females: Autism versus Borderline Personality Disorders. European Psychiatry, 67(S1), S282. https://doi.org/10.1192/j.eurpsy.2024.282

Watanabe, D., & Watanabe, T. (2023). Distinct frontoparietal brain dynamics underlying the co-occurrence of autism and ADHD. eNeuro, 10(7), ENEURO.0146-23.2023. https://doi.org/10.1523/ENEURO.0146-23.2023

Wulf, C., Kobryn, S., Ferretti, C., Rahman, A. M., & Hollander, E. (2026). Autism spectrum disorder and attention-deficit/hyperactivity disorder overlap and comorbidity in adults. Psychiatric Annals, 56(3), e65-e70. https://doi.org/10.3928/00485713-20260113-03